FDA sends message to companies partnered with Chinese drugmakers; call for greater access to monoclonals for the immunocompromised

The agency shredded the study results for an anti-PD-1 checkpoint inhibitor that Lilly licensed from its Chinese partner Innovent. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      STAT+: In attacking Lilly's cancer therapy, FDA sends message to companies partnered with Chinese drugmakers By Adam Feuerstein FDA The agency shredded the study results for an anti-PD-1 checkpoint inhibitor that Lilly licensed from its Chinese partner Innovent. Read More Opinion: Immunocompromised people need greater access to monoclonal antibodies By Luciana Borio and John P. Moore Ted S. Warren/AP The estimated 7 million Americans who are immunocompromised are especially vulnerable to Covid-19. Monoclonal antibodies may help them. Read More STAT+: South Africa's antitrust regulator wants Roche penalized for 'excessive' cancer drug pricing By Ed Silverman Jeff J Mitchell/Getty Images "The impact of excessive pricing falls heavily on women, particularly poor women, who cannot access essential treatment," the agency explained Read More Sponsor content by Astellas and Pfizer Racial disparities in prostate cancer treatment — how can we better address them? Despite the progress achieved in prostate cancer detection and care over the years, gaps in diagnosis, treatment, and outcomes still prevail among racial groups, especially among Black men. This challenge ultimately poses the question — what can physicians do to help those impacted? Learn more about disparities in prostate cancer and guidelines for certain forms of advanced prostate cancer. STAT+: 'I have a right to change my mind': A top FDA regulator is unapologetic over his about-face on Chinese cancer drugs By Adam Feuerstein FDA/Michael J. Ermarth In an interview with STAT, the FDA's Richard Pazdur acknowledged his view on Chinese cancer drugs had changed. Read More Opinion: 'Brian's Song' at 50 still offers lessons about cancer for today By Barron H. Lerner AP The hit made-for-TV movie "Brian's Song" and a related book raise issues that are relevant today for people with cancer and their families. Read More Tuesday, February 15, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser